Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Blaine Labs Inc
WARNING LETTER
•Blaine Labs Inc•September 30, 2019

Blaine Labs Inc – FDA Warning Letter, Sep 30, 2019

Record Details

The FDA inspected Blaine Labs Inc. from September 25-30, 2019, identifying significant CGMP violations for finished pharmaceuticals, rendering their drug products adulterated. The firm also manufactures "RevitaDERM PSORIASIS Treatment," an unapproved new drug.

Key violations include: 1. **Inadequate OOS Investigations (21 CFR 211.192):** The firm failed to thoroughly investigate OOS results for products like Terpenicol AFC 13% topical cream (viscosity), Tineacide Antifungal Cream 13% (stability, appearance, viscosity, assay), and a raw material (microbial contamination), leading to release of affected lots. A retrospective review of all invalidated OOS results and a comprehensive assessment of the investigation system are required. 2. **Lack of Process and Cleaning Validation (21 CFR 211.100(a)):** The firm failed to validate manufacturing processes for multiple drug products, qualify equipment, and validate cleaning processes. A detailed validation program, timeline for PPQ, and improved cleaning validation program are required. 3. **Inadequate Water System Monitoring (21 CFR 211.84(d)(6)):** The firm did not adequately monitor or validate its water system, which supplied water for drug products and equipment cleaning. A comprehensive remediation plan for the water system and a procedure for ongoing control are required. 4

Company
Blaine Labs Inc
Inspection date
September 30, 2019
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations IV
Person
  • Steven E. Porter (Program Division Director)
View Company Profile

ID · 8d38c46f-25a9-47d5-9980-7ebe49c0fa06

Violation Codes8
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121.U.S.C. 355(a)21 U.S.C. 331(d)21 U.S.C. 321(g)(1)(B)21 U.S.C. 321(g)(1)(C)21 U.S.C. 321(p)

Full citation text and observation details available on the Dashboard.

Other documents for Blaine Labs Inc
  • 483 - 2025-12-22December 22, 2025
  • 483 - 2023-12-15December 15, 2023
  • 483 - 2021-08-24August 24, 2021
  • 483 - 2019-09-30September 30, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Blaine Labs Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.